PARP1 and diffuse large B-cell lymphoma: However, addition of rituximab to CHOP was markedly more beneficial with respect to survival in ABC-DLBCL patients with high PARP1 expression than in patients with low PARP expression (HR 2.8, CI 1.6–4.7.